Eltanexor (KPT-8602)
Myelodysplastic Syndromes (MDS)
Key Facts
About Karyopharm Therapeutics
Karyopharm Therapeutics is an innovation-driven, commercial-stage company focused on discovering and developing novel oral cancer therapies targeting nuclear export. Its foundational achievement is the FDA approval of selinexor (XPOVIO®) for relapsed/refractory multiple myeloma and diffuse large B-cell lymphoma (DLBCL). The company's strategy leverages its proprietary oral SINE technology platform to expand selinexor into earlier treatment lines and new indications, while developing next-generation compounds like eltanexor and verdinexor to improve tolerability and efficacy. Karyopharm aims to establish XPO1 inhibition as a cornerstone of cancer treatment across a spectrum of malignancies.
View full company profileAbout Karyopharm Therapeutics
Karyopharm Therapeutics is an innovation-driven, commercial-stage company focused on discovering and developing novel oral cancer therapies targeting nuclear export. Its foundational achievement is the FDA approval of selinexor (XPOVIO®) for relapsed/refractory multiple myeloma and diffuse large B-cell lymphoma (DLBCL). The company's strategy leverages its proprietary oral SINE technology platform to expand selinexor into earlier treatment lines and new indications, while developing next-generation compounds like eltanexor and verdinexor to improve tolerability and efficacy. Karyopharm aims to establish XPO1 inhibition as a cornerstone of cancer treatment across a spectrum of malignancies.
View full company profileTherapeutic Areas
Other Myelodysplastic Syndromes (MDS) Drugs
| Drug | Company | Phase |
|---|---|---|
| KER-050 (Eltritercept) | Keros Therapeutics | Phase 2 |